CN1857404A - 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 - Google Patents
一种可用于治疗病毒性肝炎的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1857404A CN1857404A CN 200610058534 CN200610058534A CN1857404A CN 1857404 A CN1857404 A CN 1857404A CN 200610058534 CN200610058534 CN 200610058534 CN 200610058534 A CN200610058534 A CN 200610058534A CN 1857404 A CN1857404 A CN 1857404A
- Authority
- CN
- China
- Prior art keywords
- ganciclovir
- add
- ethanol
- viral hepatitis
- treating viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 33
- 201000001862 viral hepatitis Diseases 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title abstract description 19
- 229940079593 drug Drugs 0.000 title description 7
- 229960002963 ganciclovir Drugs 0.000 claims abstract description 80
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000000178 monomer Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 claims description 94
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 33
- 239000007924 injection Substances 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- -1 alkali metal salt Chemical class 0.000 claims description 6
- 239000000890 drug combination Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 5
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 5
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 5
- 229930014456 matrine Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 4
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000005325 percolation Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 3
- 229930183118 Tanshinone Natural products 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 235000020374 simple syrup Nutrition 0.000 claims description 3
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 235000008504 concentrate Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000008901 benefit Effects 0.000 abstract description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract description 2
- 229940010454 licorice Drugs 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 21
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 21
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 241000700605 Viruses Species 0.000 description 17
- 229960002687 ganciclovir sodium Drugs 0.000 description 15
- 239000008187 granular material Substances 0.000 description 15
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 208000002672 hepatitis B Diseases 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 7
- 206010013786 Dry skin Diseases 0.000 description 7
- 101710142246 External core antigen Proteins 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229930015582 oxymatrine Natural products 0.000 description 7
- 239000007779 soft material Substances 0.000 description 7
- 241000700721 Hepatitis B virus Species 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940126678 chinese medicines Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 230000000642 iatrogenic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 206010011830 Cytomegalovirus hepatitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940014461 combivir Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Abstract
Description
HBeAg(cpm) | HBsAg(cpm) | |
给药组 | 58.62±5.88 | 82.48±4.08 |
阳性对照组 | 40.22±8.14 | 63.64±5.20 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100585345A CN100415232C (zh) | 2006-03-14 | 2006-03-14 | 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100585345A CN100415232C (zh) | 2006-03-14 | 2006-03-14 | 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1857404A true CN1857404A (zh) | 2006-11-08 |
CN100415232C CN100415232C (zh) | 2008-09-03 |
Family
ID=37296392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100585345A Expired - Fee Related CN100415232C (zh) | 2006-03-14 | 2006-03-14 | 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100415232C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552280A (zh) * | 2011-09-09 | 2012-07-11 | 中国科学院生物物理研究所 | 甘草酸或盐及其衍生物的制药用途 |
CN113476413A (zh) * | 2021-08-09 | 2021-10-08 | 海南海灵化学制药有限公司 | 一种注射用更昔洛韦钠冻干粉的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1663568A (zh) * | 2004-03-01 | 2005-09-07 | 孙明杰 | 一种新的有效防治病毒性感染的复方制剂 |
-
2006
- 2006-03-14 CN CNB2006100585345A patent/CN100415232C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552280A (zh) * | 2011-09-09 | 2012-07-11 | 中国科学院生物物理研究所 | 甘草酸或盐及其衍生物的制药用途 |
CN113476413A (zh) * | 2021-08-09 | 2021-10-08 | 海南海灵化学制药有限公司 | 一种注射用更昔洛韦钠冻干粉的制备方法 |
CN113476413B (zh) * | 2021-08-09 | 2022-06-28 | 海南海灵化学制药有限公司 | 一种注射用更昔洛韦钠冻干粉的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100415232C (zh) | 2008-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101033245A (zh) | 具栖冬青苷的制备方法及应用 | |
CN1561994A (zh) | 治疗类风湿性关节炎和免疫性疾病的含青蒿提取物药物组合物 | |
CN1857404A (zh) | 一种可用于治疗病毒性肝炎的药物组合物及其制备方法 | |
CN1293898C (zh) | 治疗病毒性肝炎的药物组合物的制备方法 | |
CN1857285A (zh) | 一种用于治疗心脑血管疾病的胶囊及其制备方法和应用 | |
CN1186091C (zh) | 一种治疗肝病的注射液及其生产工艺 | |
CN103251876B (zh) | 一种治疗慢性肝病的中药组合物及其用途 | |
CN1679658A (zh) | 一种治疗艾兹病的中药制剂及其加工方法 | |
CN101032534A (zh) | 救必应总皂苷的制备方法及应用 | |
CN1730023A (zh) | 一种抗肝炎病毒的中药制剂及其制备方法 | |
CN1839920A (zh) | 黄芪总苷注射剂及其制备方法 | |
CN1562055A (zh) | 一种治疗肝脏疾病的药物组合物 | |
CN1947767A (zh) | 一种治疗及预防小儿智力低下药物及其制备方法 | |
CN1682819A (zh) | 四黄泻火滴丸及其制备方法 | |
CN1742783A (zh) | 一种扶正益气天然药物制剂及其制备方法 | |
CN1695717A (zh) | 一种治疗肝病的药物组合物及其制备方法和用途 | |
CN1679693A (zh) | 一种治疗肝病的药物及其制备方法 | |
CN1079396A (zh) | 增智药物制剂增智素 | |
CN1872138A (zh) | 一种可用于治疗糖尿病的药用组合物及其制备方法 | |
CN1557415A (zh) | 一种治疗肝胆疾病的药物制剂及其制备方法 | |
CN1431011A (zh) | 用于治疗肝炎的口服药物 | |
CN1795901A (zh) | 一种清热解毒、利湿退黄的药物 | |
CN1650919A (zh) | 一种中药复方制剂的处方及其制剂制备方法和用途 | |
CN1651002A (zh) | 一种中药药物组合物及制备方法和应用 | |
CN1602917A (zh) | 生脉制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 8, Gucheng West Road, Shijingshan District, Beijing, zip code: 100043 Co-patentee after: Jilin Yixin pharmaceutical Limited by Share Ltd. Patentee after: Beijing Guodan Medicine Technology Development Co.,Ltd. Address before: 8, Gucheng West Road, Shijingshan District, Beijing, zip code: 100043 Co-patentee before: Jilin A-Think Pharmaceutical Co.,Ltd. Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20090320 Address after: No. 1, one heart road, Shuangyang Economic Development Zone, Jilin, Changchun: 130616 Patentee after: Jilin Yixin pharmaceutical Limited by Share Ltd. Address before: 8, Gucheng West Road, Shijingshan District, Beijing, zip code: 100043 Co-patentee before: Jilin Yixin pharmaceutical Limited by Share Ltd. Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: JILIN YIXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING GUO DAN DRUG TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20090320 |
|
C56 | Change in the name or address of the patentee |
Owner name: JILIN A-THINK PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: JILIN YIXIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 130616 Jilin province Changchun Shuangyang Economic Development Zone on the road No. 1 Patentee after: SINOPHARM A-THINK PHARMACEUTICAL Co.,Ltd. Address before: 130616 Jilin province Changchun Shuangyang Economic Development Zone on the road No. 1 Patentee before: Jilin Yixin pharmaceutical Limited by Share Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080903 |